Cogent Biosciences, Inc.
COGTNASDAQHealthcare● Active
$31.52
+$0.50(+1.61%)
Market Cap$5.4B
P/E Ratio—
52W High$43.73
52W Low$5.485
Cogent Biosciences, Inc. (COGT) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · COGT · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | ($0.00B) | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.27B | $0.23B | $0.17B | $0.12B | $0.06B |
| G&A Expenses | $0.06B | $0.04B | $0.03B | $0.03B | $0.02B |
| Total Operating Expenses | $0.33B | $0.28B | $0.21B | $0.15B | $0.08B |
| Operating Income | ($0.33B) | ($0.28B) | ($0.21B) | ($0.15B) | ($0.08B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.01B | $0.02B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.33B) | ($0.26B) | ($0.19B) | ($0.14B) | ($0.07B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.33B) | ($0.26B) | ($0.19B) | ($0.14B) | ($0.07B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.55 | $-2.46 | $-2.42 | $-2.26 | $-1.85 |
| Wtd Avg Shares | 0.07B | 0.10B | 0.08B | 0.06B | 0.04B |
| EBITDA | ($0.33B) | ($0.27B) | ($0.20B) | ($0.14B) | ($0.07B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Cogent Biosciences, Inc. data
About Cogent Biosciences, Inc. (COGT) Income Statement
Cogent Biosciences, Inc. (COGT) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, COGT reported revenue of $0.00B, gross profit of ($0.00B) (gross margin —), and net income of ($0.33B) — a net profit margin of —.
Frequently asked questions
COGT · 4 questionsCogent Biosciences, Inc. (COGT) reported revenue of $0.00B for 2025, down —% year-over-year.
COGT revenueCOGT salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08